M Ventures

m-ventures.com ↗Activity from announced rounds

All recorded activity

M Ventures is Merck KGaA’s strategic venture investor in biotechnology, scientific tools, electronics and frontier technology. Explore its recorded Funding activity.

Investment focus

M Ventures is the strategic corporate venture investor of Merck KGaA, Darmstadt, Germany. Its mandate spans drug development, life-science tools, electronics, frontier technology and sustainability. The team combines financial and strategic objectives and works with founders and co-investors to bring scientific and technical developments toward commercial use.

Activity recorded by RoundOS

RoundOS records activity across both sides of that mandate: drug developers Remepy, TwoStep Therapeutics and TRIMTECH; research-tool businesses Lightcast and Vizgen; and optical-interconnect companies Quintessent and Polaris Electro-Optics. These published financing records describe the activity captured here, rather than the firm’s complete portfolio.

Sources
Rounds participated in
11
Confirmed lead rounds
2
6 roles undisclosed
New companies
11
First participation on record · 0 follow-on
Funding in participating rounds
$450.2M
10 disclosed · full round size, not this investor’s share

By stage

Series A6
Series C+2
Seed1
Series B1
Undisclosed1

By primary sector

Biotech7
Hardware3
Industrial tech1

By country

United States6
United Kingdom3
Israel1
Switzerland1

Rounds

11 in all activity
Nouscom

Clinical-stage biotech developing neoantigen-based cancer immunotherapies.

€120MSeries D
Lead
Mueon

Develops modular three-dimensional compute and memory systems for AI infrastructure.

$65MSeries A
Participant
Polaris Electro-Optics

Optical interconnect technology for moving data between AI and data-center systems with lower power consumption.

$50MSeries B
Participant
TwoStep Therapeutics

A peptide-targeting platform is advancing conjugate and radioligand therapies for solid tumors.

$62.5MSeries A
Role not disclosed
Quintessent

Makes quantum dot laser chips for AI datacenter optical interconnects

$40MSeries A
Role not disclosed
Remepy

Develops Hybrid Drugs combining prescription medicines with AI-driven therapeutic apps

$36MSeries A
Role not disclosed
TRIMTECH Therapeutics

Develops small molecule therapies to degrade protein aggregates in neurodegenerative diseases

$47MSeed+
Role not disclosed
STORM Therapeutics

STORM Therapeutics develops cancer medicines that target enzymes responsible for chemical modifications to RNA.

$56MSeries C
Participant
Lightcast

Develops functional single-cell analysis tools and platforms for life science research

$27MUndisclosed
Role not disclosed
Vizgen

Builds technologies for spatial biology and multi-omics innovation

$48MSeries A
Role not disclosed
ChEmpower

ChEmpower develops abrasive-free materials for semiconductor wafer polishing.

$18.7MSeries A
Lead